Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...

Star point guard commit, Eli Ellis, has earned back-to-back MVP honors in the prestigious Overtime Elite (OTE) league, widely ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Defense Secretary Pete Hegseth has ordered senior military and Defense Department officials to draw up plans to cut 8 percent ...

As HR's strategic role evolves, people professionals must leverage tech alongside human skills to drive success, says BVI ...

Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years, Eli Lilly has been a fairly safe bet to ...

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...

Here are 5 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years.

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...